Dr. Catherine Lindon

Biography

Catherine Lindon is a research group leader in the Department of Pharmacology at the University of Cambridge, where she investigates ubiquitin-mediated signaling in cell division. She developed an interest in cell biology during her time at the Institut Pasteur in Paris, prior to undertaking postdoctoral studies focusing on the control of myogenic cell fate. Lindon returned to the UK through the Wellcome Trust Advanced Training Fellowship, enhancing her expertise in cell cycle research in the Gurdon Institute group. In 2008, she became a research group leader in the Department of Genetics and transitioned to the Department of Pharmacology in 2015. Her research focuses on ubiquitin pathways that regulate the cell cycle in human cells, with a specific emphasis on the Anaphase-Promoting Complex (APC/C) and its role in mitosis. Her work includes studying Aurora kinase, a significant substrate of APC/C, which is linked to cancer and serves as a therapeutic target. Recent projects have involved developing small molecules for targeted protein degradation using PROTACs, collaborating with AstraZeneca and the Itzhaki Lab. Lindon's research is supported by organizations including BBSRC, Royal Society, and AstraZeneca.

Research Interests